About Beijing Biostar Technologies
Beijing Biostar Technologies is a company based in Beijing (China) founded in 2002. Beijing Biostar Technologies has raised $135.23 million across 2 funding rounds from investors including Matrix Partners China, CCB International and Tianjin Venture Capital. The company has 147 employees as of December 31, 2024. Beijing Biostar Technologies operates in a competitive market with competitors including Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.
- Headquarter Beijing, China
- Employees 147 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Beijing Biostar Pharmaceuticals Co., Ltd. Class H
-
Annual Revenue
$10.03 M (USD)5.82as on Dec 31, 2024
-
Net Profit
-$20.07 M (USD)25.61as on Dec 31, 2024
-
EBITDA
-$22.33 M (USD)24.21as on Dec 31, 2024
-
Total Equity Funding
$135.23 M (USD)
in 2 rounds
-
Latest Funding Round
$135.23 M (USD), Series E
Nov 26, 2020
-
Investors
Matrix Partners China
& 6 more
-
Employee Count
147
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Beijing Biostar Technologies
Beijing Biostar Technologies is a publicly listed company on the HKEX with ticker symbol 2563 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Beijing Biostar Technologies
Beijing Biostar Technologies has successfully raised a total of $135.23M across 2 strategic funding rounds. The most recent funding activity was a Series E round of $135.23 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Beijing Biostar Technologies
Beijing Biostar Technologies has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Matrix Partners China, CCB International and Tianjin Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by this venture capital firm.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Venture capital investments are managed for innovative company growth.
|
Locked | Locked | Locked |
Investor details for Beijing Biostar Technologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Beijing Biostar Technologies
Investment portfolio details for Beijing Biostar Technologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Beijing Biostar Technologies
Detailed financials for Beijing Biostar Technologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Beijing Biostar Technologies Comparisons
Peer comparison for Beijing Biostar Technologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Beijing Biostar Technologies
Beijing Biostar Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical and biotechnology company
|
|
| Locked | Locked | Locked |
Contract development, manufacturing, and analytical services for APIs are offered.
|
|
| Locked | Locked | Locked |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| Locked | Locked | Locked |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| Locked | Locked | Locked |
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
|
|
| Locked | Locked | Locked |
APIs are developed and manufactured for therapeutic areas.
|
Detailed competitors of Beijing Biostar Technologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Beijing Biostar Technologies
Complete news archive for Beijing Biostar Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Beijing Biostar Technologies
Beijing Biostar Technologies was founded in 2002 and raised its 1st funding round 17 years after it was founded.
Beijing Biostar Technologies is headquartered in Beijing, China.
Qiu Rongguo is the current CEO of Beijing Biostar Technologies.
Beijing Biostar Technologies is a funded company, having raised a total of $135.23M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Beijing Biostar Technologies is 147.
Annual revenue of Beijing Biostar Technologies is $10.03M as on Dec 31, 2024.
Beijing Biostar Technologies was founded in 2002 in Beijing, China, within the biotechnology and pharmaceutical sector. APIs, intermediates, and biochemical reagents are developed and manufactured by the company. Development services are provided, encompassing biomedical development, technology transfer for anti-tumor small molecules, and technical consulting. Operations are centered in China, supporting pharmaceutical research and production needs.
Beijing Biostar Technologies's top competitors include Laurus Labs, Symbiotec and Sterling Pharma Solutions.
Yes, Beijing Biostar Technologies is publicly traded on HKEX under the ticker symbol 2563.
Beijing Biostar Technologies has 7 investors. Key investors include Matrix Partners China, CCB International, Tianjin Venture Capital, unknown, and SDIC Venture Capital.
The ticker symbol of Beijing Biostar Technologies is 2563 on HKEX.